BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22(4): 1461-1476 [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 56] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen WT, Lee MS, Chang CL, Chiu CT, Chang ML. Retinol-binding protein-4 expression marks the short-term mortality of critically ill patients with underlying liver disease: Lipid, but not glucose, matters. Sci Rep 2017;7:2881. [PMID: 28588245 DOI: 10.1038/s41598-017-03096-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen W, Li XM, Li AL, Yang G, Hu HN. Hepatitis C Virus Increases Free Fatty Acids Absorption and Promotes its Replication Via Down-Regulating GADD45α Expression. Med Sci Monit 2016;22:2347-56. [PMID: 27381636 DOI: 10.12659/msm.899591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Monroy-Ramirez HC, Galicia-Moreno M, Sandoval-Rodriguez A, Meza-Rios A, Santos A, Armendariz-Borunda J. PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. Int J Mol Sci 2021;22:8298. [PMID: 34361064 DOI: 10.3390/ijms22158298] [Reference Citation Analysis]
4 Ocaña-Mondragón A, Mata-Marín JA, Uriarte-López M, Bekker-Méndez C, Alcalá-Martínez E, Ribas-Aparicio RM, Uribe-Noguéz LA, Rodríguez-Galindo DM, Martínez-Rodríguez ML. Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients. Biomed Rep 2018;8:85-90. [PMID: 29399341 DOI: 10.3892/br.2017.1012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Thaker SK, Ch'ng J, Christofk HR. Viral hijacking of cellular metabolism. BMC Biol 2019;17:59. [PMID: 31319842 DOI: 10.1186/s12915-019-0678-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 48.5] [Reference Citation Analysis]
6 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
7 Chen CW, Cheng JS, Chen TD, Le PH, Ku HP, Chang ML. The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts. Therap Adv Gastroenterol 2019;12:1756284819855732. [PMID: 31244896 DOI: 10.1177/1756284819855732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Chang SW, Cheng ML, Shiao MS, Yeh CT, Wang CH, Fan CM, Chiu CT, Chang ML. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation. J Clin Lipidol 2018;12:756-66. [PMID: 29574072 DOI: 10.1016/j.jacl.2018.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
9 Cardoso AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, Moraes-Coelho HS, Villela-Nogueira CA. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP). J Viral Hepat 2018;25:1244-50. [PMID: 29768686 DOI: 10.1111/jvh.12930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chang ML, Yang SS. Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology. Cells 2019;8:E1423. [PMID: 31726658 DOI: 10.3390/cells8111423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
11 Chang ML, Hu JH, Pao LH, Lin MS, Kuo CJ, Chen SC, Fan CM, Chang MY, Chien RN. Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice. BMC Immunol 2021;22:54. [PMID: 34380427 DOI: 10.1186/s12865-021-00445-5] [Reference Citation Analysis]
12 Chang ML, Cheng ML, Chang SW, Tang HY, Chiu CT, Yeh CT, Shiao MS. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity. Amino Acids. 2017;49:291-302. [PMID: 27830380 DOI: 10.1007/s00726-016-2360-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
13 Shousha HI, Abdelaziz RA, Azab SM, Khairy M, Afifi SA, Mehrez MI, Eshra MA, Abdelrahim AY. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C. J Med Virol 2018;90:1099-105. [PMID: 29469217 DOI: 10.1002/jmv.25062] [Reference Citation Analysis]
14 Lin YM, Sun HY, Chiu WT, Su HC, Chien YC, Chang HA, Chong LW, Chang HC, Young KC, Bai CH, Tsao CW. Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation. Biomed Res Int 2019;2019:3102414. [PMID: 30984779 DOI: 10.1155/2019/3102414] [Reference Citation Analysis]
15 Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol 2017;16:215-20. [PMID: 31153414 DOI: 10.5604/16652681.1231581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
16 Abo El-Khair SM, Arafa M, Besheer T, El-Eraky AM, Elsamanoudy AZ. The Association of XRCC1 Gene Polymorphisms and Chronic Hepatitis C Induced Insulin Resistance in Egyptian Patients. Cells 2018;7:E185. [PMID: 30366460 DOI: 10.3390/cells7110185] [Reference Citation Analysis]
17 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021; 27(17): 1959-1972 [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
18 Kanda T, Moriyama M. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World J Gastroenterol 2017; 23(31): 5645-5649 [PMID: 28883690 DOI: 10.3748/wjg.v23.i31.5645] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lee KC, Cheng YT, Lin CY, Kuo CJ, Chien RN, Yeh CT, Chang ML. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. Eur J Clin Invest 2020;50:e13189. [PMID: 31782138 DOI: 10.1111/eci.13189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chang ML, Kuo CJ, Pao LH, Hsu CM, Chiu CT. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance. Virulence 2017;8:1255-64. [PMID: 28267407 DOI: 10.1080/21505594.2017.1300734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Chang ML, Lin YS, Pao LH, Huang HC, Chiu CT. Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance. Sci Rep. 2017;7:42503. [PMID: 28211910 DOI: 10.1038/srep42503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
22 Ramos-Lopez O, Roman S, Martinez-Lopez E, Fierro NA, Gonzalez-Aldaco K, Jose-Abrego A, Panduro A. CD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection. World J Hepatol 2016; 8(25): 1067-1074 [PMID: 27660673 DOI: 10.4254/wjh.v8.i25.1067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
23 Cheng JS, Lin YS, Hu JH, Chang MY, Ku HP, Chien RN, Chang ML. Impact of Interferon-Based Therapy on Hepatitis C-Associated Rheumatic Diseases: A Nationwide Population-Based Cohort Study. J Clin Med 2021;10:817. [PMID: 33671397 DOI: 10.3390/jcm10040817] [Reference Citation Analysis]
24 Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, Bonometti R, Bianco S, Re A, Favretto S, Bellomo G, Minisini R, Carnevale Schianca GP, Pirisi M. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One 2018;13:e0209216. [PMID: 30571711 DOI: 10.1371/journal.pone.0209216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
25 Chang ML, Chang SW, Chen SC, Chien RN, Hsu CL, Chang MY, Fann CSJ. Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals. Viruses 2021;13:464. [PMID: 33799903 DOI: 10.3390/v13030464] [Reference Citation Analysis]
26 Chang ML, Hsu CM, Lin CH, Lin CY, Kuo CJ, Huang SW, Chen CW, Cheng HT, Yeh CT, Chiu CT. The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance. Nutrients. 2017;9. [PMID: 28574439 DOI: 10.3390/nu9060570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Hu JH, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. Exp Ther Med 2019;18:3568-78. [PMID: 31602234 DOI: 10.3892/etm.2019.7995] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
30 Chu YY, Cheng JS, Wu TS, Chen CW, Chang MY, Ku HP, Chien RN, Chang ML. Association between Hepatitis C Virus Infection and Esophageal Cancer: An Asian Nationwide Population-Based Cohort Study. J Clin Med 2021;10:2395. [PMID: 34071668 DOI: 10.3390/jcm10112395] [Reference Citation Analysis]
31 Abdelkader RY, Abdelrazek MA, Attallah A, Farid K, El-Far M. High blood glucose levels are associated with fibrosis/cirrhosis progression in chronic hepatitis C. J Immunoassay Immunochem 2021;:1-12. [PMID: 33886414 DOI: 10.1080/15321819.2021.1911813] [Reference Citation Analysis]
32 Chang ML, Chen WT, Hu JH, Chen SC, Gu PW, Chien RN. Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter. Virulence 2020;11:1501-11. [PMID: 33135589 DOI: 10.1080/21505594.2020.1838742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Abdelaziz AO, Shousha HI, Said EM, Soliman ZA, Shehata AA, Nabil MM, Abdelmaksoud AH, Elbaz TM, Abdelsalam FM. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2018;30:1384-8. [PMID: 30179227 DOI: 10.1097/MEG.0000000000001196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
35 Gerresheim GK, Roeb E, Michel AM, Niepmann M. Hepatitis C Virus Downregulates Core Subunits of Oxidative Phosphorylation, Reminiscent of the Warburg Effect in Cancer Cells. Cells 2019;8:E1410. [PMID: 31717433 DOI: 10.3390/cells8111410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
36 Chang ML, Lin YS, Chang MY, Hsu CL, Chien RN, Fann CS. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study. Virulence 2021;12:270-80. [PMID: 33446046 DOI: 10.1080/21505594.2020.1870080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Powdrill MH, Desrochers GF, Singaravelu R, Pezacki JP. The role of microRNAs in metabolic interactions between viruses and their hosts. Curr Opin Virol 2016;19:71-6. [PMID: 27475325 DOI: 10.1016/j.coviro.2016.07.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
38 Abenavoli L, Boccuto L. Adiponectin serum level changes and its dynamic relationship with hepatitis C during viral clearance. Virulence 2017;8:1069-71. [PMID: 28375793 DOI: 10.1080/21505594.2017.1315498] [Reference Citation Analysis]
39 Hu JH, Chen MY, Yeh CT, Lin HS, Lin MS, Huang TJ, Chang ML. Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area. Medicine (Baltimore) 2016;95:e3546. [PMID: 27149466 DOI: 10.1097/MD.0000000000003546] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
40 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021; 27(13): 1267-1282 [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Li X, Gao Y, Xu H, Hou J, Gao P. Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients. Sci Rep. 2017;7:9087. [PMID: 28831144 DOI: 10.1038/s41598-017-09825-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kuniholm MH, Liang H, Anastos K, Gustafson D, Kassaye S, Nowicki M, Sha BE, Pawlowski EJ, Gange SJ, Aouizerat BE, Pushkarsky T, Bukrinsky MI, Prasad VR. Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women. AIDS 2017;31:2483-92. [PMID: 29120899 DOI: 10.1097/QAD.0000000000001648] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Gonzalez-Aldaco K, Roman S, Torres-Valadez R, Ojeda-Granados C, Torres-Reyes LA, Panduro A. Hepatitis C virus clearance and less liver damage in patients with high cholesterol, low-density lipoprotein cholesterol and APOE ε4 allele. World J Gastroenterol 2019; 25(38): 5826-5837 [PMID: 31636475 DOI: 10.3748/wjg.v25.i38.5826] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Andrade VG, Yamashiro FDS, Oliveira CV, Kurozawa LL, Moreira A, Silva GF. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION? Arq Gastroenterol 2018;55:184-7. [PMID: 30043871 DOI: 10.1590/S0004-2803.201800000-33] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Cheng YT, Cheng JS, Lin CH, Chen TH, Lee KC, Chang ML. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study. Clin Microbiol Infect. 2020;26:366-372. [PMID: 31229596 DOI: 10.1016/j.cmi.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
47 Keogh A, Şenkardeş S, Idle JR, Küçükgüzel ŞG, Beyoğlu D. A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells. Metabolites 2017;7:E23. [PMID: 28574427 DOI: 10.3390/metabo7020023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
48 Purdy JG, Luftig MA. Reprogramming of cellular metabolic pathways by human oncogenic viruses. Curr Opin Virol 2019;39:60-9. [PMID: 31766001 DOI: 10.1016/j.coviro.2019.11.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
49 Pedersen MR, Patel A, Backstedt D, Choi M, Seetharam AB. Genotype specific peripheral lipid profile changes with hepatitis C therapy. World J Gastroenterol 2016; 22(46): 10226-10231 [PMID: 28028371 DOI: 10.3748/wjg.v22.i46.10226] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
50 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 2016;6:30799. [PMID: 27477870 DOI: 10.1038/srep30799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
52 Chang ML, Kuo CJ, Huang HC, Chu YY, Chiu CT. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. PLoS One 2016;11:e0166712. [PMID: 27870883 DOI: 10.1371/journal.pone.0166712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
53 Yoo H, Lee JM, Yoon JH, Kang HJ, Lee SM, Yang HK, Han JK. T2* Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment? Korean J Radiol. 2017;18:682-690. [PMID: 28670163 DOI: 10.3348/kjr.2017.18.4.682] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
54 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
55 Chang ML, Yang Z, Yang SS. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int J Mol Sci 2020;21:E8308. [PMID: 33167521 DOI: 10.3390/ijms21218308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
56 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]